Eric Lefkofsky Receives Funding for Personalizing Cancer Care

Who is Eric Lefkofsky and what is Tempus? Lefkofsky is the Co-Founder of Groupon, along with several other businesses, including Tempus. Tempus is a cutting edge technology company that gathers data in order to improve cancer care. The company is now receiving funding in order to continue down the path of cancer research and care for individuals. Lefkofsky continues to spearhead the use of technology in order to benefit patients.

Tempus has recently received 80 million dollars in funding from groups of new and existing investors. With this new funding, they are able to continue to grow the company. At already 400 employees, they need the funding in order to add more workforce to drive their mission. Success is something that Eric Lefkofsky is used to seeing as co-founder of several innovative companies. He wants to use the newest technology in order to continue the best care for cancer patients across the United States.

Tempus likes to focus on improving care. They gather data based on treatment that was provided to previous patients, then use that to evaluate the best goals. The leadership team works together in order to personalize care by collecting large volumes of information, to find what will provide the most advantages. As a team they are excited to see technology continue to help patients during their most vulnerable time.

As part of the Lefkofsky Family Foundation, the private charitable foundation aims to fund medical research. The foundation, Co-Chaired by Eric Lefkofsky, along with his wife, focuses on providing care to those who are in need, with a focus on acute cancer research. Having a history of Cancer in their family has propelled them to both look for ways to cure cancer, and increase quality of life.
If Lefkofsky can continue to empower doctors to find ways to evaluate cancer for the benefits of patients, then he is meeting his lifelong goals within his company. He continues to strive for efforts in doing so, and promoting that Tempus will be the company to promote better healthcare for citizens.

Eric Lefkofsky’s Social Media: www.facebook.com/eplefkofsky/

Dr. Clay Siegall and Seattle Genetics: Targeting Treatment Through Innovation

Seattle Genetics has been gaining recognition in the world of biotech research and is quickly becoming an authority on cancer treatment. It’s exactly what Dr. Clay Siegall hoped would become of his startup.

Seattle Genetics has recruited the best researchers in the field of cancer treatment to better develop drug therapy to better tailor treatment for patients. Dr. Siegall has been instrumental in the firm’s development, which builds upon his personal interest in the intersection between medicine and technology. It’s something that originated when a family member fell ill, and the reaction to traditional administration of chemotherapy wasn’t well received. He knew there had to be an alternative.

Seattle Genetics gets a great deal of its funding through the sale of medication, and more is awaiting approval from the FDA before it hits the market. This has increased the number of partnerships the firm has been able to obtain, furthering the Seattle Genetics brand by increasing its reach across the medical field. Dr. Siegall has noted that this continued involvement also assists in the FDA recognizing the importance of their research and give their medication more consideration in the evaluation process.

When getting the firm off the ground, Dr. Siegall noted that he had to personally engage investors and partners in order to have Seattle Genetics taken seriously in an emerging industry. Now that things are progressing positively, Siegall sees the future of his firm as secure, and that’s due in no small part to a culture of hard work and dedication to patient care that’s found throughout Seattle Genetics.

 

About Dr. Clay Siegall:

 

Dr. Clay Siegall graduated from George Washington University with a Ph.D. in Genetics, giving a platform that allowed him to serve as a member of the National Institutes of Health and the National Cancer Institute until 1999 when he departed these organizations to join Bristol-Myers Squibb Pharmaceutical Research Institute.

Dr. Siegall founded Seattle Genetics, a firm that researches and develops alternative cancer treatment methods that don’t incorporated traditional applications of chemotherapy. As Chief Executive Officer, President, and Chairman of the Board of Directors, Dr. Siegall applies his influence as an authority in the field of biomedical research to help secure more tan $675 million in public and private funding. Though is leadership, Seattle Genetics managed to have several medications approved by the FDA.